NDA 020596 · Viiv Hlthcare
Epivir
Lamivudine · Oral · Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Accelerated approvalPriority reviewLast checked: Nov 19, 2026Latest source record: May 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Nov 17, 1995
Approved uses
6
Original approval plus efficacy supplements
Registered trials
737
226 Phase 3, 25 recruiting
FAERS reports
30,839
29,623 serious, 4,112 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EXACERBATIONS OF HEPATITIS B and DIFFERENT FORMULATIONS OF EPIVIR Exacerbations of Hepatitis B Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued EPIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue EPIVIR and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions ( 5.1 )]. Important Differences among Lamivudine-Containing Products EPIVIR tablets and oral solution (used to treat HIV-1 infection) contain a higher dose of the active ingredient (lamivudine) than EPIVIR-HBV tablets and oral solution (used to treat chronic HBV infection). Patients with HIV-1 infection...
What it is approved for
From the label in effect Aug 15, 2024.
EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. Limitations of Use: • The dosage of this product is for HIV‑1 and not for HBV. EPIVIR is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. Limitations of Use: The dosage of this product is for HIV‑1 and not for HBV. ( 1 )
Mechanism: Lamivudine is an antiretroviral agent [see Microbiology ( 12.4 )].
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 20, 2016 Supplement 35 · Efficacy · priority review LetterLabel
- Mar 23, 2015 Supplement 32 · Efficacy LabelLetter
- Jun 24, 2002 Supplement 16 · Efficacy LetterLabel
- Mar 23, 1999 Supplement 7 · Efficacy Review
- Apr 11, 1997 Supplement 2 · Efficacy · priority review
- Nov 17, 1995 Original approval · Type 3 - New Dosage Form · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
1 products under this application
- EPIVIR · LAMIVUDINE 10MG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Lamivudine" as an intervention, any sponsor and status, largest first.
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- The Partners Scale-Up ProjectCompleted
University of WashingtonAcademic, hospital or other
NCT03052010 · 4,898 participants · Start Feb 6, 2017 · Primary completion Dec 15, 2020
Drug: PrEP; ART · For: HIV-1-infection
Sites: Kisumu, Kenya; Thika, Kenya
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited CountriesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01061151 · 3,747 participants · Start Mar 1, 2011 · Primary completion Sep 30, 2016
Drug: Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers and 6 more · For: HIV Infections
Sites: Pune, India; Blantyre, Malawi; Lilongwe, Malawi · 14 sites in all
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive WomenPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02181933 · 2,648 participants · Start Apr 1999 · Primary completion Jan 2001
Drug: Nevirapine; Zidovudine (ZDV) and 1 more · For: HIV Infections
- Breastfeeding, Antiretroviral, and Nutrition StudyPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00164736 · 2,369 participants · Start Mar 2004 · Primary completion Jan 2010
Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Infant nevirapine · For: HIV Infections
Sites: Lilongwe, Malawi
- The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV DrugsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00002368 · 2,000 participants
Drug: Nevirapine; Lamivudine · For: HIV Infections
Sites: Montgomery, Alabama; Los Angeles, California; Palo Alto, California · 53 sites in all
- Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South AfricaActive, not recruiting
Professor Francois VenterAcademic, hospital or other
NCT07006246 · 1,900 participants (planned) · Start May 19, 2023 · Primary completion Nov 30, 2025
Drug: Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) · For: HIV Infection
Sites: Johannesburg, South Africa
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy2,040
- drug resistance1,960
- virologic failure1,960
- drug interaction1,871
- pathogen resistance1,774
- viral mutation identified1,671
- depression1,343
- pyrexia1,279
- drug ineffective1,165
- anaemia1,126
- pain1,122
- nausea1,079
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,143 |
| 2005 | 1,218 |
| 2006 | 1,265 |
| 2007 | 1,049 |
| 2008 | 1,114 |
| 2009 | 1,084 |
| 2010 | 763 |
| 2011 | 671 |
| 2012 | 757 |
| 2013 | 670 |
| 2014 | 805 |
| 2015 | 1,613 |
| 2016 | 2,262 |
| 2017 | 2,126 |
| 2018 | 2,122 |
| 2019 | 2,247 |
| 2020 | 2,541 |
| 2021 | 1,842 |
| 2022 | 1,853 |
| 2023 | 1,697 |
| 2024 | 864 |
| 2025 | 718 |
| 2026 | 401 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Nov 16, 2026
Epivir, Injection, 10 mg/1 mL (NDC 49702-205-48). The anticipated date that ViiV will cease distribution of the product is approximately May 14, 2027.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Epivir (Lamivudine)
2024 spending
$65K
Beneficiaries
30
186 claims
Per beneficiary
$2,165
$8.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $166,660 |
| 2021 | $137,663 |
| 2022 | $118,172 |
| 2023 | $102,524 |
| 2024 | $64,963 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
Figueroa MI, Brites C, Cecchini D, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, et al. · Lancet Infect Dis 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial.
Pereira F, Magagnoli J, Ambati M, et al. · Med 2025 · Randomized Controlled Trial, Research Support, N.I.H., Intramural
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
- Choosing NRTI combinations.
· HIV Hotline 1998 · Clinical Trial, Newspaper Article
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.